Why top brokers say surge in CSL share price will continue

Could the ASX 200 giant really offer 12.9% MORE upside?

Key points
  • The CSL share price has lifted 11% in 2023 and 23% over the last 12 months to trade at $312.35
  • And it could jump another 12.9%, according to some top brokers
  • Both Citi and Morgan Stanley are expecting big things for the company's plasma business 

The CSL Limited (ASX: CSL) share price has been on a roll lately, soaring more than 13.6% since its January low.

Right now, shares in the biotechnology giant are swapping hands for $312.35.

And it could be set to continue climbing, according to top brokers.

Here's why experts have high hopes for the S&P/ASX 200 Index (ASX: XJO) healthcare staple.

A woman researcher holds a finger up in happiness as if making the 'number one' sign with a graphic of technological data and an orb emanating from her finger while fellow researchers work in the background.

Image source: Getty Images

CSL share price could continue to soar: top brokers

ASX 200 fans will know CSL well. The company is involved with the development of medicines, influenza vaccines, and recently acquired iron deficiency-focused Vifor.

It also operates a major plasma collection business. And that side of the company appears to be bolstering hope among top experts.

Morgan Stanley is one such optimistic broker. It has an overweight rating on CSL shares, slapping them with a $354 price target, my Fool colleague James reports. That represents a potential 12.9% upside.

Citi has also given the stock a buy rating and a $313.81 price target, The Australian reports.

Both brokers appear to have followed similar paths to reach their optimistic outlooks. That's based on expectations the CSL's Behring business (offering plasma-derived and recombinant therapies) could be set to grow.

Citi reportedly points out an increase in plasma collection centres in the United States, implying demand for immunoglobulin and albumin is growing.

Both brokers note that a recent earnings release from industry peer Takeda Pharmaceutical Co Ltd (NYSE: TAK) also suggests rising demand.

Meanwhile, Morgans and Bell Potter are also said to be hopeful on the stock. Though, the CSL share price has already surpassed Morgan's $312.20 price target.

Bell Potter expects plasma volumes to grow by around 8% globally each year for the foreseeable future.

However, not all experts are so confident. Goldman Sachs is neutral on CSL and tips its share price to slump 3.6% to $302 over the coming 12 months.

Citigroup is an advertising partner of The Ascent, a Motley Fool company. Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and Goldman Sachs Group. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

Thumbs down Facebook icon over dark screen.
Broker Notes

Why these 5 ASX shares were downgraded by brokers this week

Market analysts explain why they've downgraded these ASX stocks.

Read more »

A young man goes over his finances and investment portfolio at home.
Broker Notes

Buy, hold, sell: Domino's Pizza, Super Retail, PLS shares

Let's check out some new ratings on ASX shares today.

Read more »

Smiling woman taking a video through a plane window with her phone.
Broker Notes

Qantas or Virgin shares. Which ASX airline has more upside?

Will either share take off soon?

Read more »

A little girl wearing wonky glasses checks out what's happening in the world on a mobile phone.
Broker Notes

Buy, hold, sell: Paladin Energy, Accent, Sigma Healthcare shares

Experts reveal the reasons behind their new ratings.

Read more »

A woman looks excited as she fans out a wad of Aussie $100 notes.
Broker Notes

Macquarie predicts 90% upside and an 8% dividend yield for this ASX share

If the broker is right, this share will pay off nicely.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

ASX 200 healthcare shares rebound 57% in 5 months. Here's 1 to buy and 1 to sell: experts

It's time to take profits on one share, while the other has more growth left, say these experts.

Read more »

Young man with a laptop in hand watching stocks and trends on a digital chart.
Broker Notes

Buy, hold, sell: Fortescue, Santos, CBA shares

Let's review some new expert ratings and insights on 3 ASX 200 heavyweights.

Read more »

An unhappy man in a suit sits at his desk with his arms crossed staring at his laptop screen as the PointsBet share price falls
Broker Notes

BHP, Westpac, CSL shares: Buy, sell, or hold?

One of these ASX shares is tipped to fall 13%.

Read more »